In vivo Efficacy of Azlocillin and Amikacin versus Ciprofloxacin with and without Amikacin in Experimental Right-Sided Endocarditis due to Pseudomonas aeruginosa

Chemotherapy ◽  
1986 ◽  
Vol 32 (4) ◽  
pp. 364-373 ◽  
Author(s):  
Arnold S. Bayer ◽  
Kwang Sik Kim
Keyword(s):  
Pseudomonas Aeruginosa ◽  
In Vivo Efficacy

In vivo efficacy and pharmacokinetics of biapenem in a murine model of ventilator-associated pneumonia with Pseudomonas aeruginosa

2012 ◽  
Vol 18 (4) ◽  
pp. 472-478 ◽  
Author(s):  
Koichi Yamada ◽  
Katsunori Yanagihara ◽  
Yosuke Harada ◽  
Yoshitomo Morinaga ◽  
Nobuko Araki ◽  
...  
Keyword(s):  
Pseudomonas Aeruginosa ◽  
Murine Model ◽  
Ventilator Associated Pneumonia ◽  
In Vivo Efficacy

scholarly journals Humanized Exposures of Cefiderocol, a Siderophore Cephalosporin, Display Sustained in vivo Activity against Siderophore-Resistant Pseudomonas aeruginosa

Pharmacology ◽  
2018 ◽  
Vol 101 (5-6) ◽  
pp. 278-284 ◽  
Author(s):  
Islam M. Ghazi ◽  
Marguerite L. Monogue ◽  
Masakatsu Tsuji ◽  
David P. Nicolau
Keyword(s):  
Pseudomonas Aeruginosa ◽  
Bacterial Density ◽  
Infection Model ◽  
Test Panel ◽  
In Vivo Efficacy ◽  
Preclinical Data ◽  
Variable Activity ◽  
Susceptibility Profiles ◽  
Phenotypic Susceptibility

We evaluated the in vivo efficacy of humanized exposures of cefiderocol, a novel siderophore cephalosporin, against a test panel of P. aeruginosa (PSA) previously shown to develop resistance to 2 preclinical candidate siderophores (MB-1 and SMC-3176). In the thigh infection model, the PSA bacterial density in untreated controls grew from 5.54 ± 0.23 to 8.68 ± 0.57 log10 CFU over 24 h. The humanized cefiderocol exposure resulted in >1 log10 CFU reduction in all 8 isolates, while MB-1 and SMC-3176 exhibited variable activity similar to that previously reported. Humanized exposures of cefepime and levofloxacin, acting as positive antimicrobial controls displayed activity consistent with that of the bacterial phenotypic susceptibility profiles. Cefiderocol manifested in vivo efficacy against all PSA isolates including those resistant to cefepime and levofloxacin in contrast to its predecessor siderophore compounds. These preclinical data are supportive of further evaluation of cefiderocol in the treatment of P. aeruginosa.

scholarly journals KPC Presence in Pseudomonas aeruginosa Has Minimal Impact on the In Vivo Efficacy of Carbapenem Therapy

2012 ◽  
Vol 57 (2) ◽  
pp. 1086-1088 ◽  
Author(s):  
M. Hagihara ◽  
J. L. Crandon ◽  
C. M. Urban ◽  
D. P. Nicolau
Keyword(s):  
Pseudomonas Aeruginosa ◽  
In Vivo Efficacy ◽  
Minimal Impact

scholarly journals In Vivo Efficacy of 1- and 2-Gram Human Simulated Prolonged Infusions of Doripenem against Pseudomonas aeruginosa

2009 ◽  
Vol 53 (10) ◽  
pp. 4352-4356 ◽  
Author(s):  
Jared L. Crandon ◽  
Catharine C. Bulik ◽  
David P. Nicolau
Keyword(s):  
Pseudomonas Aeruginosa ◽  
Animal Studies ◽  
Multidrug Resistant ◽  
Free Time ◽  
In Vivo Efficacy ◽  
Gram Negative ◽  
Wide Range ◽  
Gram Negative Organisms

ABSTRACT Doripenem is a new carbapenem antimicrobial with activity against a range of gram-negative organisms, including Pseudomonas aeruginosa. Previous animal studies have shown efficacy of a 500-mg dose of doripenem given as a 4-h infusion against P. aeruginosa with MICs of ≤4 μg/ml. The purpose of this study is to evaluate the efficacy of 1- and 2-g-dose prolonged infusions of doripenem against a wide range of P. aeruginosa isolates in the neutropenic murine thigh model. Eighteen clinical P. aeruginosa isolates (MIC range, 2 to 32 μg/ml) were used; 15 of these were multidrug resistant. After infection, groups of mice were administered doripenem doses designed to simulate the free time above the MIC (fT>MIC) observed in humans given 1 or 2 g of doripenem every 8 h as a 4-h infusion. Efficacy correlated well with published fT>MIC bactericidal targets of 40%. After 24 h, 1- and 2-g doses achieved approximately ≥2 log decreases in CFU against isolates with MICs of ≤8 and 16 μg/ml, respectively (fT>MIC range, 52.5 to 95%). Results with organisms with higher MICs, where fT>MIC was 0%, were variable, including both increases and decreases in CFU. Compared with 1-g doses, statistically greater efficacy was noted for 2-g doses against three of the eight isolates with MICs of ≥16 μg/ml. While MIC distributions of P. aeruginosa at present necessitate increased exposures for only the most-resistant isolates, the ability of increased doses to achieve pharmacodynamic targets and the efficacy observed when these targets were attained could prove useful when these resistant isolates are encountered.

Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps

2007 ◽  
Vol 57 (2) ◽  
pp. 153-161 ◽  
Author(s):  
Christine T. Ong ◽  
Pamela R. Tessier ◽  
Chonghua Li ◽  
Charles H. Nightingale ◽  
David P. Nicolau
Keyword(s):  
Pseudomonas Aeruginosa ◽  
Efflux Pumps ◽  
In Vivo Efficacy

In vivo efficacy of ceftolozane against Pseudomonas aeruginosa in a rabbit experimental model of pneumonia: Comparison with ceftazidime, piperacillin/tazobactam and imipenem

2014 ◽  
Vol 44 (3) ◽  
pp. 218-221 ◽  
Author(s):  
Cédric Bretonnière ◽  
David Boutoille ◽  
Jocelyne Caillon ◽  
Cyndie Desessard ◽  
Christophe Guitton ◽  
...  
Keyword(s):  
Pseudomonas Aeruginosa ◽  
Experimental Model ◽  
In Vivo Efficacy
Sign in / Sign up

Export Citation Format

Share Document